Amalgamated Bank Sells 168 Shares of Align Technology, Inc. (NASDAQ:ALGN)

Amalgamated Bank reduced its position in shares of Align Technology, Inc. (NASDAQ:ALGN) by 1.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,491 shares of the medical equipment provider’s stock after selling 168 shares during the period. Amalgamated Bank’s holdings in Align Technology were worth $3,022,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. True Wealth Design LLC grew its holdings in Align Technology by 10,700.0% during the 3rd quarter. True Wealth Design LLC now owns 108 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 107 shares during the last quarter. Neo Ivy Capital Management acquired a new position in shares of Align Technology during the third quarter worth $32,000. Quarry LP grew its stake in shares of Align Technology by 74.8% in the third quarter. Quarry LP now owns 222 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 95 shares during the last quarter. Versant Capital Management Inc increased its holdings in Align Technology by 212.2% in the fourth quarter. Versant Capital Management Inc now owns 231 shares of the medical equipment provider’s stock valued at $48,000 after purchasing an additional 157 shares during the period. Finally, Newbridge Financial Services Group Inc. bought a new position in Align Technology during the 4th quarter worth $52,000. Institutional investors and hedge funds own 88.43% of the company’s stock.

Align Technology Trading Up 0.7 %

Shares of ALGN opened at $187.03 on Friday. The stock has a 50 day moving average of $211.95 and a 200 day moving average of $223.41. Align Technology, Inc. has a 12 month low of $183.24 and a 12 month high of $335.40. The company has a market capitalization of $13.96 billion, a price-to-earnings ratio of 33.34, a PEG ratio of 2.24 and a beta of 1.67.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.96 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.43 by ($0.47). Align Technology had a return on equity of 13.84% and a net margin of 10.54%. As a group, equities research analysts predict that Align Technology, Inc. will post 7.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ALGN. Piper Sandler cut their price objective on Align Technology from $275.00 to $270.00 and set an “overweight” rating on the stock in a research note on Thursday, February 6th. Evercore ISI boosted their price target on shares of Align Technology from $240.00 to $260.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Jefferies Financial Group decreased their price objective on shares of Align Technology from $285.00 to $260.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Bank of America boosted their target price on shares of Align Technology from $200.00 to $206.00 and gave the company an “underperform” rating in a report on Friday, December 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Align Technology in a report on Thursday, February 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $269.91.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.